{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:53:34Z","timestamp":1788951214362,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>5-fluorouracil (5FU) and capecitabine are fluoropyrimidine anti-neoplastic drugs commonly used in the treatment of different types of cancer. Hereditary dihydropyrimdine deaminase (DPD), thymidylate synthase mutations and drug overdose may lead to life-threatening toxicities. Uridine triacetate (UTA) is an emergency treatment for overdoses and early onset, severe or life-threatening toxicities from fluoropyrimidines. It is approved for use in adults and children within 96\u00a0h of last fluoropyrimidine administration. We present the case of a 64-year-old male treated with 5-FU and oxaliplatin as adjuvant systemic therapy for stage IIIA rectal cancer who developed delayed central nervous system toxicity 18 days after initiating chemotherapy. He had rapidly worsening encephalopathy and ataxia. Laboratory workups, MRI brain and EEG were negative. He was started on UTA with concerns of 5-FU toxicity due to the life-threatening nature of his condition even beyond the recommended 96-h time cut-off. He had rapid improvement in clinical status and resolution of encephalopathy. DPD deficiency testing later resulted as heterozygous for IVS14+1G&amp;gt;A allele indicating enzyme deficiency. This report demonstrates the importance of identifying delayed side effects with fluoropyrimidine therapy and potential treatment for reversing these effects. We also did an extensive literature review and obtained reports from the uridine triacetate clinical trials on patients receiving UTA after the 96-h cut-off. Based on our experience and previous published reports, a patient developing life-threatening delayed 5-FU toxicity should also be considered for UTA on a case-by-case basis.<\/jats:p>","DOI":"10.3389\/fphar.2022.977734","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T07:37:08Z","timestamp":1662536228000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Aasems","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janeesh","family":"Sekkath Veedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insija","family":"Selene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2050313x18786405","DOI":"10.1177\/2050313x18786405","article-title":"Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications","volume":"6","author":"Baldeo","year":"2018","journal-title":"SAGE Open Med. Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e13505","DOI":"10.1200\/jco.2010.28.15_suppl.e13505","article-title":"Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency","volume":"28","author":"Borstel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3346\/jkms.2001.16.3.328","article-title":"5-fluorouracil-induced leukoencephalopathy in patients with breast cancer","volume":"16","author":"Choi","year":"2001","journal-title":"J. Korean Med. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1477-7819-12-264","article-title":"Fatal outcome of posterior \"reversible\" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen","volume":"12","author":"Dedi\u0107 Plaveti\u0107","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/cad.0000000000000987","article-title":"Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?","volume":"31","author":"Di Federico","year":"2020","journal-title":"Anticancer. Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3109\/07357909409038226","article-title":"Cerebral demyelination with 5-fluorouracil and levamisole","volume":"12","author":"Fassas","year":"1994","journal-title":"Cancer Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/jbiol69","article-title":"Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system","volume":"7","author":"Han","year":"2008","journal-title":"J. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"421325","DOI":"10.1100\/2012\/421325","article-title":"Local treatment of hand-foot syndrome with uridine\/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaT","volume":"2012","author":"Hartinger","year":"2012","journal-title":"Sci. World J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.4172\/2167-1052.1000e125","article-title":"Pharmacogenetics-guided dosing for fluoropyrimidines in cancer chemotherapy","volume":"3","author":"He","year":"2014","journal-title":"Adv. Pharmacoepidemiol. Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1200\/JCO.2000.18.1.167","article-title":"Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies","volume":"18","author":"Hidalgo","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ana.410310306","article-title":"Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole","volume":"31","author":"Hook","year":"1992","journal-title":"Ann. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1158\/1078-0432.CCR-16-0638","article-title":"FDA approval: Uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs","volume":"22","author":"Ison","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.clcc.2021.03.002","article-title":"Use of uridine triacetate to reverse severe persistent myelosuppression following 5-fluorouracil exposure in a patient with a c.557A>G heterozygous DPYD variant","volume":"20","author":"Leung","year":"2021","journal-title":"Clin. Colorectal Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e6874","DOI":"10.1097\/md.0000000000006874","article-title":"Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature","volume":"96","author":"Mitani","year":"2017","journal-title":"Med. Baltim."},{"key":"B16","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/15563650.2019.1636569","article-title":"North American congress of clinical toxicology (NACCT) abstracts","volume":"57","year":"2019","journal-title":"Clin. Toxicol. (Phila)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00280-005-0129-x","article-title":"5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): Toxicity reduction and increased antitumor activity in mice","volume":"58","author":"Saif","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.ajem.2016.11.038","article-title":"The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV\/AIDS with uridine triacetate","volume":"35","author":"Santos","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/07357909909021422","article-title":"Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"17","author":"Shehata","year":"1999","journal-title":"Cancer Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4103\/0019-509x.178423","article-title":"Irreversible cerebellar toxicity after infusional 5-flurouracil therapy","volume":"52","author":"Suresh","year":"2015","journal-title":"Indian J. Cancer"},{"key":"B21","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"B22","volume-title":"Vistogard [package insert]","year":"2015"},{"key":"B23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1078155217732141","article-title":"Successful use of uridine triacetate (vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature","volume":"25","author":"Zurayk","year":"2019","journal-title":"J. Oncol. Pharm. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.977734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T07:37:13Z","timestamp":1662536233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.977734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":23,"alternative-id":["10.3389\/fphar.2022.977734"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.977734","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"article-number":"977734"}}